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Abstract—The discovery of important biomarkers is a signif-
icant step towards understanding the molecular mechanisms of
carcinogenesis; enabling accurate diagnosis for, and prognosis of,
a certain cancer type. Before recommending any diagnosis, ge-
nomics data such as gene expressions (GE) and clinical outcomes
need to be analyzed. However, complex nature, high dimensional-
ity, and heterogeneity in genomics data make the overall analysis
challenging. Convolutional neural networks (CNN) have shown
tremendous success in solving such problems. However, neural
network models are perceived mostly as ‘black box’ methods
because of their not well-understood internal functioning. How-
ever, interpretability is important to provide insights on why
a given cancer case has a certain type. Besides, finding the
most important biomarkers can help in recommending more
accurate treatments and drug repositioning. Moreover, the ‘right
to explanation’ of the EU GDPR gives patients the right to know
why and how an algorithm made a diagnosis decision. Hence, in
this paper, we propose a new approach called OncoNetExplainer
to make explainable predictions of cancer types based on GE
data. We used genomics data about 9,074 cancer patients covering
33 different cancer types from the Pan-Cancer Atlas on which
we trained CNN and VGG16 networks using guided-gradient
class activation maps++ (GradCAM++). Further, we generate
class-specific heat maps to identify significant biomarkers and
computed feature importance in terms of mean absolute impact
to rank top genes across all the cancer types. Quantitative
and qualitative analyses show that both models exhibit high
confidence at predicting the cancer types correctly giving an
average precision of 96.25%. To provide comparisons with the
baselines, we identified top genes, and cancer-specific driver
genes using gradient boosted trees and SHapley Additive ex-
Planations (SHAP). Finally, our findings were validated with the
annotations provided by the TumorPortal.
Index Terms—Cancer genomics, Gene expression, Neural net-
works, GradCAM++, Interpretability, Explainable AI.
I. INTRODUCTION
Cancer is caused by gene alterations and abnormal be-
haviors of genes that control cell division and cell growth.
The change in the structure of occurring genetic aberrations,
such as somatic mutations, copy number variations (CNV),
profiles, and different epigenetic alterations are unique for
each type of cancer [1,2]. As a result, gene expressions (GE)
can be disrupted by cell division or environmental effects, or
genetically inherited from parents. Changes in GE sometimes
change the production of different proteins, affecting normal
cell behavior. These damaged cells start reproducing more
rapidly than usual and gradually increase in the affected area
by forming a tumor. Intermittently, such tumors turn into
a type of cancer [3,4]. This is one of the utmost reasons
cancer incidences are gradually increasing every year and
have become the second leading cause of death worldwide.
Consequently, more than 200 types of cancer have been
identified, each of which can be characterized by different
molecular profiles requiring unique therapeutic strategies [1].
The most common cancers diagnosed in men are prostate,
lung, and colorectal cancers, while for women, breast, lung,
and colorectal cancers are most common [5].
As the importance of genetic knowledge in cancer treatment
is increasingly addressed, several projects have emerged , of
which The Cancer Genome Atlas (TCGA) most well-known
for omics data. TCGA curates various omics data, e.g., gene
mutation, gene expressions (GE), DNA methylation, CNV, and
miRNA expressions. By acquiring deep insights of these data,
treatment can be focused on preventive measures. Besides,
clinical outcomes, i.e., clinical and pathology information are
provided. TCGA further analyzed over 11,000 cancer cases
from 33 prevalent forms of cancer, which fostered the accom-
plishment of the Pan-Cancer Atlas (PCA), which results from
the normalized GE data about 20K protein-coding genes [6].
These data, however, are highly variable, high-dimensional,
and sourced from heterogeneous platforms, which imposes
significant challenges to existing bioinformatics tools stimu-
lating the development of deep learning (DL)-based diagnosis
and prognosis systems. Since DL algorithms work better with
such high dimensional data, recent studies focused on using
deep architectures such as autoencoders, CNN, and Recurrent
Neural Networks (RNN). Although these models have shown
tremendous success in exhibiting high confidence, they are
mostly perceived as ‘black box’ methods because of a lack of
understanding of their internal functioning. This is a serious
drawback since interpretability is essential to generate insights
on why a given cancer case is of a certain type, and since
knowing the most important biomarkers can help in recom-
mending more accurate treatments and drug repositioning.
Further, the ‘right to explanation’ of the EU GDPR [7] gives
patients the right to know why and how an algorithm made a
diagnosis decision. However, existing approaches can neither
ensure the diagnosis transparently nor are they trustworthy.
Since GE data are very high dimensional and a significant
number of genes have a trivial effect on the tumor making
them very weak features, we hypothesize that our approach
called OncoNetExplainer based on neural networks (NN) and
ML baselines with the explanation capability can be more
effective at learning hierarchical features. We trained and
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evaluated CNN and VGG16 networks with a guided-gradient
class activation map (GradCAM++) [8]. Using GradCAM++,
we generated heat maps (HM) for all the classes showing
prominent pixels across GE values and computed the feature
importance in terms of mean absolute impact (MAI) to iden-
tify important biomarkers and provide interpretations of the
predictions to make the cancer diagnosis transparent. Further,
we validated our findings through functional analysis to make
sure the selected genes are biologically trustworthy for the
corresponding tumor types. Further, SHAP is used along with
GBT to validate our findings based on the annotations provided
by the TumorPortal to ensure the consistency and accuracy.
The rest of the paper is structured as follows: section II dis-
cusses related works and highlights their potential limitations.
Section III chronicles data collection and preparation before
constructing and training the network. Section IV demonstrates
some experimental results and discusses the key findings of
the study. Section V provides explanations and points out the
relevance of the study, highlights its limitations and discusses
future works before concluding the paper.
II. RELATED WORK
Numerous approaches using genomic data, bioimaging,
and clinical outcomes have been proposed for analyzing ge-
nomic profiles of patients for treatment decision making [5].
However, early detection of tumors is particularly important
for better treatment of patients, a notable issue being the
discrimination of tumor samples from normal ones [9]. Un-
like conventional cancer typing methods that work based on
morphological appearances, GE levels of the tumor are used
to differentiate tumors that have similar histo-pathological
appearances, giving more accurate tumor typing results for
colorectal cancer diagnosis [10]. Different types of mutation
data, e.g., point mutation, single nucleotide variation, INDEL,
and CNV are also used. Yuan et al. [11] observed that these
genomics phenomena are associated with complex diseases
and contribute to the growth of different types of cancers.
Different ML algorithms were trained using mixed data
types, e.g., genomic data, bioimaging data, and clinical out-
comes. These approaches not only proved useful at improving
cancer prognosis, diagnosis, and treatments but also revealed
subtype information of several cancer types [12]. Li et al. [5]
employs a genetic algorithm for feature selection and a k-
nearest neighbors for the classification based on GE data from
the PCA project. Their approach can classify 90% of the tumor
cases correctly using different 20-gene sets. However, since the
data contain GE values of more 20K protein-coding genes,
these generic ML methods were found to be inefficient, with
some genes appearing repeatedly in the sets because of the
curse of dimensionality. Since DL algorithms work better with
high dimensional data, recent studies focused on employing
NN architectures, which in comparison with traditional ML-
based approaches, have shown more accurate and promising
results for cancer identification. In particular, CNN has shown
tremendous success and has gained much attention for solving
gene selection and classification based on microarray data [13].
Further, Cruz et al. [2] trained a CNN using whole slide
images, and extract deep features from different cohorts, which
are used to detect cancer regions. Danaee et al. [14] used a
stacked denoising autoencoder to extract features from RNA-
seq data, which are then fed into a SVM and a shallow ANN to
classify malignant or benign tumors of breasts [15]. Although
their study makes predictions on the cancer predisposition of
unseen test groups of mixed DNAs with high confidence, it
is limited to only Caucasian and Korean cohorts. Elsadek et
al. [16] used CNVs about 23,082 genes for 2,916 instances
from cBioPortal to classify the tumor samples of breast,
bladder urothelial, colon, glioblastoma, kidney, and head and
neck squamous cells and achieve an accuracy of 85%.
Lyu et al. [6] and Mostavi et al. [17] embedded the RNA-
Seq data from the PCA project into 2D images and trained
a CNN to classify 33 tumor types, which outperforms the
approach in [5]. Besides, they provide a functional analysis on
the genes with high intensities in the HM based on GradCAM
and validated that these top genes are related to tumor-specific
pathways. However, due to the stochastic nature of NN,
the prediction and feature importance generated is slightly
different across runs, i.e., not deterministic. This is also no
exception for tree-based ensemble models such as gradient
boosted trees (GBT), which provides 3 options for measuring
feature importance: i) weight, which is the number of times
a feature is used to split the data across all trees, ii) cover,
the number of times a feature is used to split the data across
all trees weighted by the number of training data points go
through those splits, and iii) gain, which is the average training
loss reduction gained when using a feature for splitting. Based
on these measure, feature importance orderings (i.e., the order
in which features were added) are different since subsequent
features will get a disproportionately high weight.
Our proposed approach OncoNetExplainer first embeds high
dimensional RNA-Seq data into 2D images and trains CNN
and VGG16 networks with GradCAM++ activated to classify
33 tumor types based on patients’ GE profiles and provides a
human-interpretable explanation (post-model explainability) to
identify important biomarkers, which is further validated based
on the annotations from TumorPortal. To provide a comparison
with baselines, we also identify the top-K biomarkers for each
cancer type and cancer specific driver genes based on GBT and
SHAP (pre-model explainability).
III. MATERIALS AND METHODS
In this section, we discuss the data preparation, network
construction, training, and biomarkers discovery with ranking.
A. Data collection and preparation
We use the cancer transcriptomes from the Pan-Cancer
Atlas project to interrogate GE states induced by deleterious
mutations and copy number alterations. In particular, GE
profiles about 33 prevalent tumor type for 9,074 samples are
used in our approach. This dataset has been used widely as
prior knowledge to generate tumor-specific biomarkers [18–
20]. These data are hybridized by the Affymetrix 6.0 , which
allows us to examine the largest number of cases along
with the highest probe density [21]. Table I shows sample
distribution. To apply the convolutional (conv) operations,
TABLE I: Sample distribution across different tumor types
Cohort #Sample Carcinoma type
BRCA 981 Breast invasive carcinoma
LGG 507 Brain lower grade glioma
UCEC 507 Uterine endometrial carcinoma
LUAD 502 Lung adeno-carcinoma
HNSC 487 Head-neck squamous cell carcinoma
THCA 480 Thyroid carcinoma
PRAD 479 Prostate adeno-carcinoma
LUSC 464 Lung squamous cell carcinoma
BLCA 398 Bladder urothelial carcinoma
STAD 383 Stomach adeno-carcinoma
SKCM 363 Skin cutaneous melanoma
KIRC 352 Kidney renal clear cellcarcinoma
LIHC 348 Liver hepato-cellular carcinoma
COAD 341 Colon adeno-carcinoma
CESC 272 Cervical & endo-cervical cancer
KIRP 271 Kidney papillary cell carcinoma
SARC 229 Sarcoma
OV 176 Ovarian serouscystadenocarcinoma
ESCA 169 Esophageal carcinoma
PCPG 161 Pheochromocytoma-paraganglioma
PAAD 152 Pancreatic adenocarcinoma
TGCT 144 Testicular germ cell tumor
GBM 124 Glioblastoma multiforme
THYM 119 Thymoma
READ 118 Rectum adeno-carcinoma
LAML 115 Acute myeloid leukemia
MESO 82 Mesothelioma
UVM 80 Uveal melanoma
ACC 76 Adrenocortical cancer
KICH 65 Kidney chromophobe
UCS 56 Uterine carcino-sarcoma
DLBC 37 Diffuse large B-cell lymphoma
CHOL 36 Cholangio carcinoma
we embed GE samples into 2D images in which GE values
for each sample are reshaped from a 20,501×1 array into
a 144×144 image by zero padding around the edges and
normalized to [0,255] without losing any information.
B. Network construction and training
We trained a shallow CNN from scratch alongside data
augmentation in which the output of each conv layer is passed
to dropout and Gaussian noise layers to avoid overfitting
and thus regularize the learning [22]. This involves the input
feature space into a lower-dimensional representation, which
is then further down-sampled by two different pooling layers
and a max-pooling layer (MPL) by setting the pool size. The
output of an MPL is considered as an ‘extracted feature’ from
each 2D GE image. Since each MPL ‘flattens’ the output space
by taking the highest value in a FM, this produces a sequence
vector from the last conv layer, which we expect to force
the GE value of specific genes that are highly indicative of
being responsible for a specific cancer type. Then this vector
is passed through another dropout layer and a fully connected
softmax for the probability distribution over the classes.
The CNN is trained with AdaGrad to optimize the categor-
ical cross-entropy loss of the predicted cancer type vs. actual
cancer type. Further, we observe the performance by adding
the Gaussian noise layer (GNL) following each conv layer to
improve model generalization. Further, we used the pretrained
VGG16 network to which we added two dense layers at the
end of the original architecture, followed by a GNL. Then, we
fine-tuned the top layers with minor weight updates:
• First, we instantiated the conv base of the VGG16 net-
work and loaded its weights.
• Then, we added our previously defined fully-connected
layers on top with minor weight updates.
• Finally, we placed a softmax layer by freezing up to the
last conv block of the VGG16 model, which yields a
probability distribution over 33 different classes.
Since the data is very high dimensional, we chose not to
go for manual feature selection. Rather, we let both CNN
and VGG16 networks extract the most important features.
The guided back-propagation helps to generate more human-
interpretable but fewer class-sensitive visualizations than the
saliency maps (SM) [23]. Since SM use true gradients, the
trained weights are likely to impose a stronger bias towards
specific subsets of the input pixels. Accordingly, class-relevant
pixels are highlighted rather than producing random noise [23].
Therefore, GradCAM++ is used to draw the HM to provide
attention to most important genes. Class-specific weights of
each FM are collected from the final conv layer through glob-
ally averaged gradients (GAG) of FMs instead of pooling [8]:
αck =
1
Z
∑
i
∑
j
∂yc
∂Akij
(1)
where Z is the number of pixels in a FM, c is the gradient
of the class, and Akij is the value of kth FM at (i, j). Having
gathered relative weights, the coarse SM, Lc is computed as
the weighted sum of αck ∗Akij of the ReLU activation function
and employ the linear combination to the FM, since only the
features with positive influence on the class are of interest [8].
Lc = ReLU(
∑
i
αckA
k) (2)
The GradCAM++ replaces the GAG with a weighted aver-
age of the pixel-wise gradients (eq. (3)), since the weights of
pixels contribute to the final prediction(eq. (4)) by aggregating
eq. (3) and αkcij (eq. (5)). In summary, it applies the following
iterators over the same activation map Ak, (i, j) and (a, b):
wck =
∑
i
∑
j
αkcij · ReLU(
∂yc
∂Akij
) (3)
yc =
∑
k
wck ·
∑
i
∑
j
Akij (4)
αkcij =
∂2yc
(∂Akij)
2
2 ∂
2yc
(∂Akij)
2 +
∑
a
∑
bA
k
ab
∂3yc
{(∂Akij)3}
(5)
Further, since an appropriate selection of hyperparameters
can have a huge impact on the performance of a deep archi-
tecture, we perform the hyperparameter optimization through
a random search and 5-fold cross-validation tests. In each of
5 runs, 70% of the data is used for the training, 30% for the
evaluation. 10% of the training set is used for validation of
the networks to optimize the cross-entropy loss based on the
best learning rate, batch size, number of filters, kernel size,
and dropout/Gaussian noise probability.
Algorithm 1: Computing feature importance and ranking genes
Input : 2D GE images D = (d1, d2, . . . , dn) having ground truth (i.e., labels) L = (l1, l2, . . . , lj) on which a CNN
model is trained for each fold M = (m1,m2, . . . ,mi) to find k for top-k genes that satisfy MAI threshold.
Output: feature importance F = (f1, i1)(f2, i2), . . . , (fn, in) and top features T across all images per fold per class.
for fold ∈ FOLDS do
P ← {} // Guided backprop for each image per fold per class
K ← {} // GradCAM++(GCAM) for all images per fold per class
I ← {} // GCAM of each image in a fold
G ← {} // GCAM for all images per fold per class
F ← {} // Feature importance of each gene per class per fold
T ← {} // Top genes and importance per class per fold
for d ∈ D do
K ← gradCAM ++(md, d, ld) // GCAM of images per fold per class
P ← guidedBackprop(md, d) // Guided backprop of each image
I ← K ∗ P // GCAM of each image
G ← G ∪ I // GCAM for all the images in fold
F ← 1N
∑N
i=1 G // Mean absolute impact for genes for axis=0
if Fi < σ then
// If the feature importance is less than MAI
F ← F − Fi // Pop off insignificant genes
T ← sortk(F ) // Sort and choose top genes based on MAI
Return F , T
Algorithm 2: Identification of important areas
Input : importance of current class across folds F = (f1, . . . , fi), height h & width w of rectangle, & MAI threshold σ.
Output: important areas C = (x1, y1), (x2, y2), . . . , (xn, yn) in an image per fold.
for fold ∈ FOLDS do
A ← dict() // Importance of areas
S ← list() // Sorted areas by MAI
C ← list() // Important areas
for h do
for w do
area← F [h : h+ shape[0], w : w + shape[1]] // Area of image
impA← 0 // Importance of current area in the image
for row ∈ area do
for imp ∈ row do
if imp > σ then
// If feature importance is greater than MAI
impA+ = imp − σ // Importance of area = current importance - MAI
A[area] = impA // We update the importance of the area
S ← sort(A, reverse = true)
for a, i ∈ S do
if a ∩ i = then
// Non-intersecting area with important areas
C ← C ∪ a // It’s a new important area added to the list
Return C
Fig. 1: Schematic representation of our approach, which starts from taking a raw GE sample and passing to conv layers before
obtaining rectified conv feature maps (with guided-backprop & GradCAM++) to pass through dense, dropout, & softmax layer
C. Finding and validating important biomarkers
Algorithm 1 and 2 depict the pseudocodes for computing
feature importance with ranking genes and identification of
important areas on the HM, respectively. We averaged all
the normalized HM from the same class to generate a class-
specific HM inspired by Selvaraju et al. [8]. In the HM,
a higher intensity pixel represents a higher significance to
the final prediction, which indicates higher importance of
corresponding genes and the GE values. Top genes are then
selected based on the intensity rankings and MAI threshold.
Since GradCAM++ requires all the samples to run through the
network once, we let the trained CNN models set and record
the activation maps in the forward pass, and the gradient maps
in the back-prop to collect the HM for each sample.
In contrast, Shapley values are used to calculate the impor-
tance of a feature by comparing what a model predicts with
and without a feature from all possible combinations of n
features in the dataset S. Given a GE value of feature i ∈ S,
SHAP calculates the prediction p of the model with i. The
Shapely value φ is calculated as follows [24]:
φi(p) =
∑
S⊆N/i
|S|!(n− |S| − 1)!
n!
(p(S ∪ i)− p(S)) (6)
However, since the order in which a model sees features
can affect the predictions, this computation is repeated in all
possible orders to compare the features fairly. Feature that
have no effect on the predicted value are expected to produce a
Shapley value of 0. However, if two features contribute equally
to the prediction, the Shapley values should be the same [24].
IV. EXPERIMENTS
Implementation was done in Python1 using a software
stack comprising Scikit-learn and Keras with the TensorFlow
backend. The network was trained on an Nvidia GTX 1080i
GPU with CUDA and cuDNN enabled. Results based on
hyperparameters produced through random search and 5-fold
cross-validation are reported and discussed with a comparative
analysis with macro-averaged precision and recall. Further,
1 https://github.com/rezacsedu/XAI Cancer Prediction
since the classes are imbalanced, Matthias correlation coef-
ficient (MCC) scores were reported. Since it is important
for cancer diagnosis to have both high precision and high
recall [25], results with very different precision and recall are
not useful in cancer diagnosing and tumor type identification.
Hence, we did not report F1-scores.
A. Performance of cancer type classification
The average accuracy obtained was 89.75% and 96.25%
using CNN and VGG16 models, respectively. However, since
the classes are imbalanced, only the accuracy will give a
very distorted estimation of the cancer types. Thus, we report
the class-specific classification reports along with the corre-
sponding MCC scores in table II. As can be seen, precision
and recall for the majority cancer types were high and for
these the VGG16 model performs mostly better. Notably,
the VGG16 model classifies BRCA, UCEC, LUAD, HNSC,
LUSC, THCA, PRAD, BLCA, STAD, KIRC, LIHC, COAD,
CESC, KIRP, SARC, OV, PCPG, TGCT, GBM, READ,
LAML, MESO, and DLBC cancer cases more confidently,
whereas the CNN model classifies PAAD, CHOL, and UCS
cancer cases more accurately.
Fig. 2: ROC curves of the VGG16 model across folds
The ROC curves generated by the VGG16 model in fig. 2
show that the AUC scores are consistent across the folds.This
Fig. 3: Heat map examples for selected cancer types. Each row represents the result from one fold. Columns represent the heat
maps of BRCA, KIRC, COAD, LUAD, and PRAD cancer types (patterns are not clearly visible in some folds, though)
TABLE II: Cancer type prediction: CNN vs VGG16
CNN (89.75%) VGG16 (96.25%)
Type Precision Recall MCC Precision Recall MCC
BRCA 0.8785 0.8612 0.7564 0.9437 0.9511 0.8465
LGG 0.9254 0.8926 0.8330 0.9311 0.9402 0.8421
UCEC 0.8753 0.8819 0.7835 0.9562 0.9429 0.8445
LUAD 0.8235 0.8354 0.7136 0.9865 0.9823 0.8624
HNSC 0.8520 0.8743 0.7851 0.9730 0.9822 0.8765
THCA 0.8528 0.8323 0.7275 0.9138 0.9154 0.8125
PRAD 0.8827 0.8778 0.7847 0.9233 0.9347 0.8207
LUSC 0.8726 0.8634 0.7625 0.9434 0.9472 0.8524
BLCA 0.8956 0.9037 0.8075 0.9656 0.9537 0.8475
STAD 0.8253 0.8156 0.6932 0.9653 0.9556 0.8532
SKCM 0.8853 0.8711 0.8025 0.9046 0.9136 0.8168
KIRC 0.8967 0.9123 0.8237 0.9578 0.9689 0.8531
LIHC 0.8194 0.8085 0.6945 0.9572 0.9664 0.8537
COAD 0.8368 0.8245 0.7679 0.9776 0.9690 0.8514
CESC 0.8785 0.8743 0.7964 0.9873 0.9885 0.8664
KIRP 0.8254 0.8032 0.7043 0.9681 0.9782 0.8430
SARC 0.8753 0.8671 0.7835 0.9365 0.9435 0.8421
OV 0.8825 0.8733 0.7936 0.9725 0.9773 0.8262
ESCA 0.8913 0.8719 0.7951 0.8956 0.8834 0.8076
PCPG 0.8537 0.8611 0.7875 0.9875 0.9987 0.8735
PAAD 0.9629 0.9567 0.8407 0.9452 0.9500 0.8325
TGCT 0.8736 0.8722 0.7825 0.9890 0.9724 0.8434
GBM 0.8952 0.8845 0.8075 0.9362 0.9453 0.8436
THYM 0.9255 0.9123 0.8232 0.9775 0.9678 0.8622
READ 0.6795 0.6857 0.6225 0.8874 0.8733 0.7525
LAML 0.8697 0.8567 0.8237 0.9576 0.9632 0.8513
MESO 0.8991 0.9028 0.8076 0.9534 0.9456 0.8457
UVM 0.8765 0.8623 0.7979 0.9136 0.9089 0.8184
ACC 0.9217 0.9345 0.8225 0.9623 0.9731 0.8611
KICH 0.9335 0.9475 0.8425 0.9690 0.9625 0.8439
UCS 0.9157 0.9064 0.8125 0.8726 0.8675 0.7869
DLBC 0.8678 0.8729 0.7005 0.9347 0.9421 0.8389
CHOL 0.8838 0.8975 0.7979 0.8455 0.8342 0.6821
Average 0.8975 0.9065 0.8052 0.9625 0.9542 0.8453
signifies that the predictions by the VGG16 model are much
better than random guessing. Further, the class-specific MCC
scores of the VGG16 model is 4% higher than that of the
CNN model, which suggests that the predictions were strongly
correlated with the ground truth, yielding a Pearson product-
moment correlation coefficient higher than 0.70 for all the
classes except for the CHOL tumor samples. The downside,
however, is that both classifiers made a number of mistakes
Fig. 4: Common driver genes across 33 cancer types)
too, e.g., VGG16 can classify ESCA, READ, UCS, and CHOL
tumor cases in only 89% of the cases accurately, while the
CNN model made more mistakes particularly for the READ,
LUAD, LIHC, KIRP, COAD, and STAD tumor samples.
B. Feature importance and validation of top biomarkers
We identified top genes for which the change in expression
has significant impact on patients. Figure 3 shows examples
of HM generated for each class across 5 different folds. As
seen, there are similarities across folds and displaying distinct
and similar patterns when comparing different cancer types.
The red circles highlight similar patterns, e.g., between KIRC
and BRCA, and PRAD and LUAD across folds, whereas
COAD shows very different patterns. Although there are
differences among folds, some patterns are clearly visible.
Since intensities did not follow any regular pattern, we chose
top 660 genes across 33 tumor types (top-20 genes per class) as
TABLE III: Top-5 genes and their importance
Type Gene Gene type MAI
BRCA
TP53 Oncogene 0.78125
GATA3 Protein-coding 0.760784
MLL3 Protein-coding 0.664706
TBX3 Oncogene 0.574118
MPO Protein-coding 0.538039
KIRC
MTOR Oncogene 0.596078
SETD2 Protein-coding 0.560784
ATM Protein-coding 0.540784
MPO Oncogene 0.531569
AMBN Oncogene 0.523137
LUAD
EGFR Oncogene 0.860000
KEAP1 Protein-coding 0.820784
ERBB2 Oncogene 0.764706
MLL3 Protein-coding 0.674118
AMBN Protein-coding 0.558039
PRAD
FOXA1 Oncogene 0.556078
TP53 Oncogene 0.520784
ATM Protein-coding 0.510784
AMBN Protein-coding 0.491569
MED12 Protein-coding 0.453137
COAD
EPHA6 Protein-coding 0.756078
TIMP1 Protein-coding 0.720784
ART5 Protein-coding 0.680784
FOXD1 Protein-coding 0.661569
AMBN Protein-coding 0.563137
more significant based on the measure of MAI. Since we have
more than 20K protein-coding genes, our choice of 660 is still
a reasonable choice, since the number of important biomarkers
should be small whose GE changes are sensitive to cancer
growth [3]. All genes in the top-20 list can thus be viewed
as tumor-specific biomarkers, which contribute most toward
making the predictions. As for the other 29 tumor types, only
3 genes were in the list. Further hyperparameter tuning and
training of both CNN models might improve this outcome.
Then we further narrowed down the list to the top-5 genes in
which only 5 tumor types (i.e., BRCA, KIRC, COAD, LUAD,
and PRAD) have at least five genes with feature importance of
at least 0.5 w.r.t. MAI; they are shown in table III.To further
validate our findings, the saturation analyses of cancer genes
across 33 tumor types (except for COAD) are obtained from
the TumorPortal [26]. Validation for the COAD cancer follows
a signature-based approach [3], which was used for predicting
the progression of colorectal cancer. However, our approach
makes some false identifications, as 21 out of 25 genes are
validated to be correct, making only 4 false identifications.
C. Finding common biomarkers
Identifying all significant common genes will help under-
stand various aspects for a specific cancer type (e.g., BRCA
carcinogenesis). Thus, these top genes have close relations
to the corresponding tumor types, which could be viewed
as potential biomarkers. Figure 4 shows the top-10 common
biomarkers, in which KRTAP1-1, INPP5K, GAS8, MC1R,
POLR2A, BET1P1, NAT2, PSD3, KAT6A, and INTS10 genes
are common across cancer types, with the INTS protein-coding
gene having the highest feature importance of 0.6.
D. Explanations with SHAP
The GBT model is trained to provide explanations generated
by SHAP. Figure 5 shows a base value that indicates the
direction of the first prediction made by the GBT model and
shows how much each feature is pushing the model’s output
from the base value2 0.55 to the predicted output. Features
pushing the prediction higher are shown in red; those pushing
the prediction lower are in blue. Further, to get an overview
of which biomarkers are most important for the GBT model,
we plot the SHAP values of each feature for each sample.
The plot in fig. 6 sorts features by the sum of SHAP value
magnitudes over all the samples, shows the distribution of the
impact of each feature on the model output, and gives the
top-20 common biomarkers, where red represents high feature
values, blue low. This reveals, e.g., that a low NACA2 (low
GE value) lowers the predicted value. Since the common
biomarkers predicted by VGG16 (fig. 4) and GBT (fig. 6) are
very different, a more detailed analysis of biological signaling
pathways is further required to validate these findings.
E. Comparison with related works
OncoNetExplainer slightly outperforms the approach by
Boyu et al. [6] but 6.5% better than the approach by Yuanyuan
et al. [5]. Further, OncoNetExplainer can improve the false
prediction rate for the READ, UCS, ESCA, and CHOL tumor
samples. In particular, against 35%, 81%, 77%, and 56%
of the correctly predicted cases by [6], our approach can
predict 88.74%, 87.26%, 89.56%, and 84.55% (in cyan) of the
same cases correctly. Although OncoNetExplainer performs
slightly worse than [6] at classifying BRCA, THCA, and
PRAD (in red), it is more consistent for the majority of cancer
types and likely to perform more stably on new GE data.
OncoNetExplainer provides both pre-model (GBT) and post-
model interpretation (CNN and VGG16), whereas [6] provides
only the post-model interpretability. some other studies also
used GE data [16,27] for the cancer prediction. However, since
GE data from the PCA project had more samples, a one-to-one
comparison with these studies was not viable.
V. CONCLUSION AND OUTLOOK
In this paper, we proposed OncoNetExplainer, an explain-
able method for the prediction of cancer types based on GE
data. Our approach is based on GradCAM++ with CNN and
VGG16 networks, and SHAP-based GBT model. Experiment
results show that GE is useful for predicting cancer types with
high confidence giving an accuracy of up to 96.25%. We also
attempted to provide a more human-interpretable explanation
by showing statistically significant biomarkers. These analyses
are further validated with scientific literature [26], which
confirms that the identified genes are biologically relevant.
Although we attempted to open the CNN and VGG16
black-box models through biomarker validation and feature
ranking, our approach is mostly post-hoc in that the explain-
ability is based on test cases and results similar to layer-wise
relevance propagation. Several further factors have hindered
this research: i) lack of enough training samples, ii) lack of
biological pathways analysis, and iii) since multiple factors are
involved in cancer diagnosis (e.g., estrogen, progesterone, and
2 The average model output over the training dataset passed
Fig. 5: Clinical features’ contribution for the first prediction: pushing the prediction higher and lower in red and blue, respectively
Fig. 6: Clinical features ordered by ascending importance on
the y-axis (dots represent SHAP values of specific features)
epidermal growth receptors in BRCA), AI-based diagnoses
might not be trustworthy solely based on a single modality,
which demands the requirements of multimodal features of
DNA methylation, GE, miRNA expression, and CNVs data.
In the future, we intend to extend this work by: i) alleviating
more samples by combining genomics data from ICGC and
COSMIC to train a multimodal architecture, ii) improving the
explanations about the predictions using an ante-hoc approach
by seeding explainability into the model from the beginning.
In particular, we will focus on multimodality with reversed
time attention model and Bayesian deep learning [28].
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